RecruitingMalignant Neoplasm
A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)
Eligible age
18+ yrs
Accepts
All genders
Locations
3 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Researchers are looking for new ways to treat certain advanced or metastatic solid tumors. The goal of this study is to learn about the safety of MK-4716 and if people tolerate it when taken alone or with other treatments.
Sponsor: Merck Sharp & Dohme LLC
You may qualify if…
- ✓ Subset of arm MK-4716 Dose Escalation and subset of arm MK-4716 + Cetuximab: Has a confirmed diagnosis of locally advanced unresectable or metastatic solid tumor
- ✓ Subset of arm MK-4716 Dose Escalation and subset of arm MK-4716 + Cetuximab: Must demonstrate presence of Kirsten rat sarcoma viral oncogene homolog (KRAS) alteration
- ✓ Subset of arm MK-4716 Dose Escalation and subset of arm MK-4716 + Cetuximab: Has received at least 1 prior line of systemic therapy for locally advanced unresectable or metastatic disease
- ✓ Arm MK-4716 + Pembrolizumab: Has a confirmed diagnosis of metastatic non-small cell lung cancer
- ✓ Arm MK-4716 + Pembrolizumab: Must demonstrate presence of KRAS alteration
- ✓ Arm MK-4716 + Pembrolizumab: Must be untreated
- ✓ Has measurable disease
- ✓ Has the ability to swallow and retain oral medication
You may not qualify if…
- ✕ Arm MK-4716 + Pembrolizumab: Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention
- ✕ Arm MK-4716 + Pembrolizumab: Has received any prior immunotherapy and was discontinued from that treatment
- ✕ Arm MK-4716 + Pembrolizumab: Has active autoimmune disease that has required systemic treatment in the past 2 years. Hormonal supplementation (eg, thyroxine, insulin, or physiologic corticosteroid) is allowed
- ✕ History of human immunodeficiency virus infection
- ✕ Has a known additional malignancy that is progressing or has required active treatment within the past 2 years
- ✕ Has a known active central nervous system metastases and/or carcinomatous meningitis
- ✕ History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
- ✕ Has active infection requiring systemic therapy
Where it's recruiting
Source: ClinicalTrials.gov · NCT07247110 · last updated 2026-09-11